^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BTK S707Y

    i
    Other names: BTK, Bruton Tyrosine Kinase, Bruton Agammaglobulinemia Tyrosine Kinase, Tyrosine-Protein Kinase BTK, Bruton'S Tyrosine Kinase, B-Cell Progenitor Kinase, AGMX1, ATK, BPK, Tyrosine-Protein Kinase BTK Isoform (Lacking Exon 13 To 17), Dominant-Negative Kinase-Deficient Brutons Tyrosine Kinase, Tyrosine-Protein Kinase BTK Isoform (Lacking Exon 14), Truncated Bruton Agammaglobulinemia Tyrosine Kinase, Agammaglobulinaemia Tyrosine Kinase, Agammaglobulinemia Tyrosine Kinase, PSCTK1, IGHD3, IMD1, XLA, AT
    Entrez ID:
    695
    Related biomarkers:
    Expression
    Mutation
    Associations

    News

    Trials
    over3years
    Noncatalytic Bruton's tyrosine kinase activates PLCγ variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells. (PubMed, J Biol Chem)
    At high levels of B-cell receptor (BCR) activation, which may occur in individual CLL patients, catalytically-inactive BTK restored the ability of the BCR to mediate increases in [Ca]. Because catalytically-inactive BTK is insensitive to active-site BTK inhibitors, the mechanism involving the noncatalytic BTK uncovered here may contribute to preexisting reduced sensitivity or even primary resistance of CLL to these drugs.
    Journal
    |
    BTK (Bruton Tyrosine Kinase) • PLCG2 (Phospholipase C Gamma 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SYK (Spleen tyrosine kinase)
    |
    BTK C481S • PLCG2 mutation • BTK S707Y
    |
    Imbruvica (ibrutinib)